Evidence map›Paper›PMID 26749342›Full record

ArticleInternational journal of clinical pharmacy2016

Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.

Eline Vandael, Bert Vandenberk, Joris Vandenberghe, Isabel Spriet, Rik Willems, Veerle Foulon

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Development of a risk score for QTc-prolongation: the RISQ-PATH study.International journal of clinical pharmacy · 2017
    Observational
  7. Which QT Correction Formulae to Use for QT Monitoring?Journal of the American Heart Association · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Eline VandaelDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven - University of Leuven, Herestraat 49, Box 521, 3000, Leuven, Belgium. Eline.Vandael@pharm.kuleuven.be.
Bert VandenberkDepartment of Cardiovascular Sciences, KU Leuven - University of Leuven, 3000, Leuven, Belgium.
Joris VandenbergheDepartment of Neurosciences, KU Leuven - University of Leuven, 3000, Leuven, Belgium.
Isabel SprietDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven - University of Leuven, Herestraat 49, Box 521, 3000, Leuven, Belgium.
Rik WillemsDepartment of Cardiovascular Sciences, KU Leuven - University of Leuven, 3000, Leuven, Belgium.
Veerle FoulonDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven - University of Leuven, Herestraat 49, Box 521, 3000, Leuven, Belgium.
KU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany drugs, including haloperidol, are linked with a risk of QTc-prolongation, which can lead to Torsade de Pointes and sudden cardiac death.

objectiveTo investigate the prevalence of concomitant risk factors for QTc-prolongation in patients treated with haloperidol, and the use of safety measures to minimize this risk.

settingUniversity Hospitals of Leuven, Belgium. Methods A retrospective epidemiological study was performed. On 15 consecutive Mondays, all patients with a prescription for haloperidol were included. A risk score for QTc-prolongation, inspired by the pro-QTc score of Haugaa et al., was calculated based on gender, comorbidities, lab results and concomitant QTc-prolonging drugs (each factor counting for one point). Available electrocardiograms before and during the treatment of haloperidol were registered.

main outcome measureManagement of the risk of QTc-prolongation.

resultsTwo hundred twenty-two patients were included (59.0 % men, median age 77 years) of whom 26.6 % had a risk score of ≥4 (known to significantly increase the mortality). Overall, 24.3 % received haloperidol in combination with other drugs with a known risk of Torsade de Pointes. Half of the patients had an electrocardiogram in the week before the start of haloperidol; only in one-third a follow-up electrocardiogram during haloperidol treatment was performed. Of the patients with a moderately (n = 41) or severely (n = 14) prolonged QTc-interval before haloperidol, 48.8 % and 42.9 % respectively had a follow-up electrocardiogram. In patients with a risk score ≥4, significantly more electrocardiograms were taken before starting haloperidol (p = 0.020).

conclusionsAlthough many patients had risk factors for QTc-prolongation (including the use of other QTc-prolonging drugs) or had a prolonged QTc on a baseline electrocardiogram, follow-up safety measures were limited. Persistent efforts should be taken to develop decision support systems to manage this risk.

Indexed as

Hospitals, UniversityAdultAgedAged, 80 and overAntipsychotic AgentsBelgiumElectrocardiographyFollow-Up StudiesHaloperidolHumansLong QT SyndromeMiddle AgedRisk ManagementTorsades de PointesYoung AdultAntipsychotic AgentsHaloperidolHaloperidolQTc-prolongationRisk managementSudden cardiac deathTorsade de Pointes

Identifiers

PMID26749342
OpenAlexW2227804096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.